Drug Discovery World

JANUARY 9, 2024

Thirteen new-to-market therapeutics and drugs poised to launch in 2024 will achieve ‘blockbuster’ status by 2029 or deliver game-changing benefits to patients. The first approvals of RSV vaccines (RSVpreF and RSVpreF3) targeted at infants and older adults mark a significant public health milestone.

Drugs 173

Drugs Therapies Treatment Virus 173

Drug Discovery World

OCTOBER 4, 2022

This year’s event will cover some of the most exciting advancements in areas spanning screening, automation, high content imaging, disease models, cell and gene therapies and how innovation is being driven through partnerships and collaborations. Collaborations have and will always be an important part of this industry.

Drugs 130

Drugs Therapies Clinical Trials Cell Based Assays 130

The Pharma Data

MARCH 31, 2022

. €650 million fixed rate notes, due April 2029, bearing interest at an annual rate of 1.250%. million patients, provided with essential medicines by the global health unit, for the treatment of non-communicable diseases in 40 of the world’s poorest countries, between 2022 and 2026. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.

Government 52

Government Treatment Vaccine Disease 52

Vial

MARCH 1, 2024

billion by 2029. Existing lab services include bioanalytical, biomarker , and vaccine sciences labs in Virginia; a GMP lab in Ireland; central labs and biomarker operations in Belgium, Kentucky, and Singapore; and bioanalytical, biomarker, vaccine sciences, and central labs in China. from 2024 to reach US$129.8

Clinical Trials 52

Clinical Trials Clinical Research Laboratories Trials 52